BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
16.35
+0.11 (0.68%)
At close: Aug 13, 2026, 4:00 PM EDT
17.24
+0.89 (5.44%)
After-hours: Aug 13, 2026, 7:39 PM EDT
Company Description
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment.
Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
BlossomHill Therapeutics, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 7, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Jingrong Jean Cui |
Contact Details
Address: 10255 Science Center Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | (858) 732-3880 |
| Website | bhtherapeutics.com |
Stock Details
| Ticker Symbol | BLSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1839970 |
| CUSIP Number | 095130100 |
| ISIN Number | US0951301003 |
| Employer ID | 85-1578711 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| J. Jean Cui, Ph.D. | President, Chief Executive Officer, Director |
| Y. Peter Li, Ph.D., MBA | Executive Chairman |
| Jason Keyes, MBA | Chief Financial Officer, Executive Vice President |
| Vincent Liptak, J.D., Ph.D., MBA | General Counsel, Executive Vice President |
| Geoff Oxnard, M.D. | Chief Medical Officer, Executive Vice President |
| Sundeep Agrawal, M.D. | Director |
| Bihua Chen, MBA | Director |
| Carl L. Gordon, Ph.D., CFA | Director |
| Sheila Gujrathi, M.D. | Director |
| John Schmid, MBA | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | SCHEDULE 13D | Filing |
| Aug 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 7, 2026 | 424B4 | Prospectus |
| Aug 6, 2026 | EFFECT | Notice of Effectiveness |
| Aug 6, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Aug 6, 2026 | CERT | Certification by an exchange approving securities for listing |
| Aug 4, 2026 | 8-A12B | Registration of securities |
| Aug 3, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jul 17, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |